Please try another search
Mendus AB (publ), a biopharmaceutical company, develops immunotherapies for the treatment of tumor recurrence and established tumors. Its lead product is vididencel (DCP-001), which is in Phase II ADVANCE-II clinical trial for the treatment of acute myeloid leukemia (AML); Phase II CADENCE clinical trial to treat AML; and Phase I ALISON clinical trial for the treatment of ovarian cancers. The company also develops ilixadencel, which completed Phase I clinical trial for the treatment of soft tissue sarcomas; and an NK cell program, which is in a preclinical study for NK cell-based therapies. It has an alliance with NorthX Biologic to support large-scale manufacturing and commercial launch of vididencel; and the Australasian Leukaemia and Lymphoma Group to expand the clinical development of vididencel as a maintenance treatment for AML. The company was formerly known as Immunicum AB (publ) and changed its name to Mendus AB (publ) in June 2022. Mendus AB (publ) was incorporated in 2002 and is headquartered in Stockholm, Sweden.
Name | Age | Since | Title |
---|---|---|---|
Hans Preusting | 62 | 2021 | Independent Director |
Sven Andreasson | 72 | 2020 | Independent chairman |
Helen Tuvesson | 62 | 2020 | Independent Director |
Lewis L. Lanier | - | 2023 | Member of Scientific Advisory Board |
Inge Marie Svane | - | 2018 | Member of Scientific Advisory Board |
Ted Fjallman | 46 | 2023 | Independent Director |
Dharminder Singh Chahal | 48 | 2021 | Independent Director |
Tanja D. de Gruijl | - | 2021 | Member of Scientific Advisory Board |
Sjoerd van der Burg | - | 2021 | Member of Scientific Advisory Board |
Ada M. Kruisbeek | - | 2021 | Chair of Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review